The use of plasma protein therapeutics has significantly increased in medical applications. This, coupled with the rising aging population, its medicinal use in novel indications, and the advent of new plasma-derived therapies, has been propelling the market for plasma protein therapeutics. Transparency Market Research (TMR) projects the market to continue exhibiting robust growth worldwide between 2016 and 2024.
Recent advancements introduced in plasma protein therapeutics aimed at improving the quality of patient care have been pivotal in fuelling their demand. These advancements have also proven crucial in guaranteeing donor’s safety. The increasing demand for immunoglobulin (IG) and the increasing use of protein therapeutics will thus augment demand for plasma protein therapeutics. TMR expects, the global market for the same to rise at a CAGR of 7.0% between 2016 and 2024. The market stood at US$18.5 bn in 2015 and is expected to reach US$31.84 bn by the end of 2024. Despite exhibiting growth at a positive rate, stringent regulations and lack of proper reimbursement policies could hamper the market’s trajectory.
North America, trailed by Europe, Exhibits Most Lucrative Prospects for Market
Regionally, North America, Asia Pacific, Europe, Latin America, and Rest of the World constitute the most lucrative markets for plasma protein therapeutics. Among these regions, North America held the dominant share in the global market in 2015, trailed by Europe. New indications, the increasing geriatric population, and investments in novel researches are boosting prospects for the market in North America. As per TMR, the North America plasma protein therapeutics market is expected to reach US$13.8 bn by the end of 2024 from a valuation of US$7.5 bn in 2015. If the figures hold true, the regional market will exhibit a CAGR of 7.9% during the forecast period.
In Europe, demand for protein therapeutics is increasing consequent to the rise in the number of clinical indications for immunoglobulin. Since immunoglobulin finds application across hematology, neurology, dermatology, nephrology, immunology, ophthalmology, rheumatology, and others, demand for protein therapeutics in Europe is expected to remain high.
During the forecast period, TMR projects Asia Pacific to emerge as the most lucrative market for plasma protein therapeutics. The rising demand for albumin and immunoglobulin in Asia Pacific is bolstering prospects for expansion of the market in the region. Furthermore, the region is also known to import albumin and immunoglobulin from North America and Europe. China as per TMR, imports nearly half of its albumin supply in order to bridge the demand and supply gap. The albumin segment is thus expected to register the fastest growth in Asia Pacific. In Latin America, however, the plasma protein therapeutics market is restrained by low rate of diagnosis and treatment and high pricing.
Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=10424
Growth to be Facilitated by Rising Incidence of Immunodeficiency Disorders
Plasma protein therapeutics is increasingly used in the treatment of primary immunodeficiency disorder (PID). The PID segment is likely to exhibit a CAGR of 7.6% between 2015 and 2024. The PID treatment segment is poised to gain considerably from the increasing investment immunoglobulin. Furthermore, with the increasing incidence of secondary immunodeficiency disorders, applications of plasma protein therapeutics is likely to increase across the treatment of prolonged illnesses. The most common secondary immunodeficiency disorders include diabetes, myeloma, HIV infection, and under-nutrition. Despite being a rare disorder, treatment of hereditary angioedema (HAE) has become possible due to the growing awareness regarding the disease worldwide. This is expected to boost the demand for plasma protein therapeutics significantly.
Some of the leading players operating in the global plasma protein therapeutics market include
Baxter International, Biotest, CSL Behring, Grifols, S.A., Kedrion, Octapharma USA, Inc., Shire plc, and China Biologics.
Nonalcoholic Steatohepatitis Therapeutics Market Witnesses Rising Demand and Investment from R&D Activities
According to a new market report published by Transparency Market Research “Nonalcoholic Steatohepatitis Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 – 2025”, the nonalcoholic steatohepatitis (NASH) therapeutics market is anticipated to expand at a CAGR of 10.7% from 2015 to 2025 to reach US$20.27 bn by 2025.
Nonalcoholic Steatohepatitis (NASH) is a syndrome that advances in patients who are not alcoholic; it causes liver damage that is histologically indistinguishable from alcoholic hepatitis. The major feature in NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well and are not aware of their liver problem. However, NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged and no longer able to work properly. It develops most frequently in patients with at least one of the following risk factors as obesity, dyslipidemia, and glucose intolerance. Pathogenesis is not clearly understood but seems to be linked to insulin resistance. Most of the patients are asymptomatic. Laboratory outcomes include elevations in aminotransferase levels. Biopsy is essential to confirm the diagnosis. Treatment mainly focusses on elimination of causes and risk factors.
The prevalence of NASH and NAFLD is increasing across the globe but it is more in developed regions such as North America. Both NASH and NAFLD are becoming more common, perhaps because of the greater number of Americans with obesity. In the past few years, the rate of obesity has almost doubled in adults and tripled in children. Obesity also adds to diabetes and high blood cholesterol, which can further complicate the health of people suffering from NASH. Diabetes and high blood cholesterol are also becoming more common among Americans.
Currently, no specific therapies exist for NASH treatment. The most important recommendations given to persons with this disease are weight reduction (if overweight), following a balanced and healthy diet, increasing physical activity, avoiding alcohol and avoiding unnecessary medications.
The NASH market is segmented based on drug type which includes potential phase III candidates such as Obeticholic acid (OCA), Aramchol, Saroglitazar and Elafibranor. Moreover, the report enlists the candidates in Phase I and Phase II clinical trials. Based on the drug type, Elafibranor is expected to account for a major share of this market and the market for Elafibranor is expected to grow at the highest CAGR. This growth is majorly due to Elafibranor which is considered to be the most advanced drug in this category.
Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7691
Major players in this market are Astazeneca Plc (U.K.), Intercept Pharmaceuticals Inc. (U.S.), Galmed Pharmaceuticals Ltd. (Israel), GENFIT SA (France), Gilead Sciences, Inc. (U.S.), Zydus Cadila (India), Immuron Ltd. (Australia), Conatus Pharmaceuticals (U.S.), and Tobira Therapeutics, Inc. (U.S.).
The Nonalcoholic Steatohepatitis (NASH) Therapeutics market has been segmented as follows:
Global Nonalcoholic Steatohepatitis (NASH) Therapeutics Market, By Drug Type
- Potential Drug Candidates in Phase III
- Obeticholic Acid (OCA)
- Aramchol (arachidyl amido cholanoic acid)
Global Vial Adaptors for Reconstitution Drug Market: Snapshot
The global market for vial adaptors for reconstitution drugs has been experiencing a steady demand as these vial adaptors have come to be the safest solutions for quick transfer for drugs between vials. The demand for these vial adaptors is also expected to shoot up as they are exceptionally cost-effective and come with a reduced the risk of needlestick injuries. The growing prevalence of infectious diseases, widening pool of geriatrics, and increasing safety concerns have all triggered a demand for vial adaptors for reconstitution drugs. According to the research report, the global vial adaptors for reconstitution drug market was valued at US$780 mn in 2015 and is expected to reach US$1.3 bn by the end of 2024. Between the forecast years of 2016 and 2024, the global market is expected to progress at a CAGR of 7.5%.
Autoimmune Diseases to Drive Global Vial Adaptors for Reconstitution Drug Market
On the basis of therapeutic area, the vial adaptors for reconstitution drug market has been segmented into autoimmune diseases, infectious diseases, metabolic conditions, reproductive health and others. Currently, the infectious diseases segment holds a major share in the global vial adaptors for reconstitution drug therapeutic area segment. However, the autoimmune diseases segment is expected to show robust growth rate in the coming years. As of 2015, it was the second largest segment in the overall market in terms of revenue. The American Autoimmune Related Diseases Association (AARDA) states that more than 50 million individuals are affected by autoimmune disorders in the U.S. every year. This is expected to drive the autoimmune diseases segment in the coming years.
North America to Remain the Leading Regional Market during Forecast Period
In terms of geography, the global market is segmented into North America, Europe, Asia Pacific, and Rest of the World. Out of these regional markets, North America remained dominant in the global vial adaptors for reconstitution drug market in 2015. Europe followed this lead closely. The high incidence of autoimmune diseases, rising technological advancements, and growing demand for needle-free products likely to support the growth of the vial adaptors for reconstitution drug market in North America. On the other hand, the demand in Europe will be fueled by increasing advancements in healthcare technology amidst rising safety concerns.
Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=18509
Analysts estimate that Asia Pacific is also likely to be a lucrative market for the vial adaptors for reconstitution drugs during the forecast period. The growing adoption of technology, high prevalence of autoimmune diseases such as diabetes, and increasing adoption of technology are all expected to make a significant contribution to the soaring vial adaptors for reconstitution drug market in Asia Pacific. This regional market will also be propelled by the swelling pool of geriatrics, who are prone to various medical conditions and a vast pool of unmet medical needs. The strengthening economies of Asia Pacific and improving access to healthcare in the region are also likely to augment the demand for vial adaptors for reconstitution drugs.
The key players operating in the global vial adaptors for reconstitution drug market are Baxter International Inc., Becton, Dickinson and Company, Cardinal Health, Inc., Sensile Medical AG, Unilife Corporation and West Pharmaceutical Services, Inc. The market is largely consolidated as major players hold a dominating share.
Radiopharmaceutical Market: Developing Regions to Witness Steady Growth despite Small Share in Global Market
Radiopharmaceutical Market: Snapshot
The global market for radiopharmaceuticals is poised for steady growth in the coming years, driven primarily by the rising use of radioisotopes for the treatment of various diseases, such as cancer, bone palliation, neurological disorders, and cardiovascular diseases. Around 35 million patients undergo treatment procedures for these diseases each year and this will continue to boost the demand for radiopharmaceuticals.
According to the Nuclear Energy Institute, radioisotopes are essential for biomedical research in order to cure AIDS, cancer, and Alzheimer’s disease. The World Nuclear Association states that around 10,000 hospitals across the world use radioisotopes in medicines and 90% of this is dedicated toward disease diagnosis.
The global radiopharmaceutical market was valued at US$4.7 bn in 2015 and is estimated to reach US$7.4 bn by 2024, expanding at a CAGR of 5.3% from 2016 to 2024.
Growing Incidence of Cancer Driving Demand for Most Radioisotopes
Based on radioisotope, the technetium-99 segment led the global radiopharmaceuticals market, accounting for a share of 50.3% in 2015. This can be attributed to the high availability of technetium-99 from molybdenum-99, which is generated through the decay of uranium radioactive raw material inside the sources.
The 18F radioisotope segment is expected to gain market share during the forecast period due to the increase in demand for cyclotron-based radioisotopes for nuclear medicine and the advancement of technological systems such as PET and SPECT. The demand for other radioisotopes such as lutetium-177, rubidium-87, and gallium-62 is also high due to the rising demand for radioisotopes for cancer treatment, the surge in the prevalence of cardiovascular diseases, and the detection of other infectious diseases. Based on application, oncology took the lead owing to the growing use of various radioisotopes in the treatment of different cancers.
Radiopharmaceutical products are used by various end users such as hospitals, ambulatory surgical centers, and diagnostic centers. Hospitals formed the leading segment of the market in terms of revenue in 2015 due to the growing usage of radiopharmaceutical. This can be attributed to technological advancements in various systems to cure cancer patients and the rise in favorable government reimbursement policies to help patients recover their costs and provide precaution against biohazards. The ambulatory surgical centers and diagnostic centers segments are expected to gain market share by 2024 due to the introduction of advanced imaging technologies such as SPECT and PET.
Developing Regions to Witness Steady Growth despite Small Share in Global Market
The global radiopharmaceuticals market has been segmented into North America, Latin America, Asia Pacific, Europe, and the Middle East and Africa. North America led the radiopharmaceuticals market in 2015 in terms of revenue, with the U.S. emerging as the most prominent contributor to the radiopharmaceuticals market in North America. This can be attributed to the existence of several large nuclear reactors such as NRU, which accounts for a 30% to 40% share in the Mo-99 supply for the global production of nuclear medicine.
Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=213
Europe is also expected to account for a significant share by 2024 due to the increase in the number of cyclotron installations for the production of radioisotopes used in the treatment of cancer and other diseases.
The Middle East and Africa is projected to account for a small share in the global market by 2024. However, growth in this market is likely to be attributed to the introduction of cyclotrons by the IBA Group and the setting up of new nuclear reactors such as ETRR-2 in South Africa for the production of radioisotopes.
Latin America is estimated to account for a meager share by the end of the forecast period. However, it continues to be driven by the increase in domestic collaborations with foreign radiopharmaceutical companies and major suppliers of radioactive raw materials and the establishment of hospitals and ambulatory surgical centers for cancer patients.
Prominent players operating in the radiopharmaceutical market include Advanced Accelerator Applications (AAA), Eckert & Ziegler, GE Healthcare, IBA Radiopharma Solutions, Lantheus Holdings, Inc., Mallinckrodt plc., Nordion, Inc., Siemens Healthineers, and Positron Corporation.
The global synthetic biology market is projected to grow remarkably, says a report from Transparency Market Research (TMR). This report is titled “Synthetic Biology Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019”. The research study on the global synthetic biology market offers a 360-degree view of the market.
According to this report, the global synthetic biology market will expand at a 32.60% CAGR during the forecast period from 2013 to 2019. In 2012, the global synthetic biology market was worth US$1.8 bn and by 2019, the market is expected to be worth US$13.4 bn. The global synthetic biology market is driven by the growing demand for improved drugs and vaccines. Furthermore, advancement in molecular biology will also fuel the global synthetic biology market. This trend is gaining traction in the market as the participation of government bodies and universities in research on synthetic biology is rising. Furthermore, the demand for genetically modified crops (GMOs) due to the expanding global population is also driving advancement in molecular biology.
Read Full Report: http://www.transparencymarketresearch.com/synthetic-biology-market.html
By product type, the global synthetic biology market is divided into core products (chassis organisms, XNA, synthetic cells, synthetic genes, and synthetic DNA) and enabling products (oligonucleotide synthesis and DNA synthesis). In 2012, the synthetic biology market was dominated by the synthetic DNA segment due to the higher commercial availability of this product as compared to other core products.
On the basis of technology, the global synthetic biology market is divided into bioinformatics, DNA sequencing, genome engineering, and biological components and integrated systems. As genome engineering can be used for genetically modifying foods, gene therapy, and gene cloning, the application of genome engineering has grown, in turn driving the global synthetic biology market.
Application-wise, the global synthetic biology market is segmented into agriculture, chemicals, healthcare, and others. The largest market share in the global synthetic biology market is held by the healthcare sector, as there is high utilization of synthetic biology techniques to make cheap vaccines and drugs. On the other hand, the agriculture application segment of the global synthetic biology market is expected to experience the highest growth during the forecast period.
Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=421
On the basis of geography, the global synthetic biology market is classified into Asia Pacific, Europe, North America, and Rest of the World (RoW). Europe held the largest market share in the global synthetic biology market in 2012 and is projected to grow consistently in the foreseeable future. The Europe synthetic biology market benefits from the efforts of government and private firms towards the development of this field. Funding for synthetic biology research in Europe is high. The start of the €70-bn Horizon 2020 program in Europe represents a pivotal moment for this regional synthetic biology market.
Some of the key players operating in the global synthetic biology market are Amyris, Bayer, Biosearch Technologies, Genomatica, Ginkgo Bioworks, Green Biologics, and Thermo Fisher Scientific. Several of these players in the global synthetic biology market are involved in many R&D initiatives.